Table 4 Association of APOE polymorphism with the risk of T2DM, CVD, T2DM + CVD+
From: Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes
Genotype | Control (n = 211) | T2DM (n = 247) | Unadjusted OR (95% CI) | CVD (n = 232) | Unadjusted OR (95% CI) | T2DM + CVD+ (n = 234) | Unadjusted OR (95% CI) |
|---|---|---|---|---|---|---|---|
E3/E3 | 160 | 183 | 0.91 (0.60–1.39) | 144 | 0.51 (0.34–0.77)** | 139 | 0.47 (0.31–0.70)** |
E2/E3 | 24 | 16 | 0.54 (0.28–1.05) | 23 | 0.86 (0.47–1.57) | 20 | 0.73 (0.39–1.36) |
E3/E4 | 25 | 43 | 1.57 (0.92–2.66) | 46 | 1.84(1.09–3.12)* | 63 | 2.74(1.65–4.55)** |
ε2 | 26 | 20 | 0.64 (0.35–1.17) | 37 | 0.86 (0.47–1.56) | 29 | 1.02 (0.58–1.74) |
ε3 | 369 | 425 | 0.89 (0.60–1.30) | 357 | 0.48 (0.33–0.69)** | 361 | 0.49 (0.34–0.70)** |
ε4 | 26 | 46 | 1.56 (0.95–2.57) | 70 | 2.71 (1.69–4.34)** | 78 | 3.05 (1.91–4.85)** |